AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis (Child-Pugh A) in Europe

- EU label expansion supported by high cure rates shown in TURQUOISE-III study, a dedicated Phase 3b study of VIEKIRAX + EXVIERA without ribavirin for 12 weeks

- 100 percent SVR(12) (n=60/60) achieved in genotype 1b patients with compensated cirrhosis (Child-Pugh A); no patients discontinued treatment due to adverse events

Feb 26, 2016, 09:33 ET from AbbVie